PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm
Automated-Biopharmaceutical-Characterisation

Automated Biopharmaceutical Characterisation: From Early Development to Quality Control (QC)

The biophysical characterisation of biopharmaceuticals is critical to the development of a well-controlled large-scale production process. Moreover, as patents expire, the number of biosimilar candidates is rapidly rising, and the abbreviated development pathway associated with these molecules places a heightened emphasis on biophysical characterisation as a means to prove similarity. Guillaume Tremintin and Stuart Pengelley of Bruker Daltronics suggest that the complexity of a protein´s heterogeneity profile, compared to small molecules, demands a number of complementary techniques to achieve sufficient characterisation.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/05/Automated-biopharmaceutical-characterisation.pdf” width=”100%” height=”900px” style=”border:0;”]

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC